Jazz Pharmaceuticals (JAZZ) said Monday it that Co-founder, Chairperson and Chief Executive Bruce Cozadd plans to retire.
Cozadd will retire as CEO upon the appointment of his replacement, which is expected by the end of 2025, but will continue as chairperson of the board, according to the company.
The company said its board will start a formal search process for a new CEO.
Jazz also said it remains on track to meet its full year 2024 total revenue guidance of between $4.0 billion and $4.1 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments